These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19349537)

  • 1. Irinogenetics: how many stars are there in the sky?
    Mathijssen RH; Gurney H
    J Clin Oncol; 2009 Jun; 27(16):2578-9. PubMed ID: 19349537
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
    Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
    J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
    Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
    Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
    Teft WA; Welch S; Lenehan J; Parfitt J; Choi YH; Winquist E; Kim RB
    Br J Cancer; 2015 Mar; 112(5):857-65. PubMed ID: 25611302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity.
    Kroetz DL
    J Clin Oncol; 2006 Sep; 24(26):4225-7. PubMed ID: 16895999
    [No Abstract]   [Full Text] [Related]  

  • 6. Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.
    Takano M; Kato M; Yoshikawa T; Goto T; Furuya K; Kikuchi Y
    Int J Clin Oncol; 2010 Apr; 15(2):224-5. PubMed ID: 20179984
    [No Abstract]   [Full Text] [Related]  

  • 7. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
    Takane H; Kawamoto K; Sasaki T; Moriki K; Moriki K; Kitano H; Higuchi S; Otsubo K; Ieiri I
    Cancer Chemother Pharmacol; 2009 May; 63(6):1165-9. PubMed ID: 18998132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
    Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
    Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
    Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K
    Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UGT1A and irinotecan toxicity: keeping it in the family.
    Hoskins JM; McLeod HL
    J Clin Oncol; 2009 May; 27(15):2419-21. PubMed ID: 19364959
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
    Ichikawa W; Araki K; Fujita K; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Kodama K; Sunakawa Y; Narabayashi M; Ando Y; Akiyama Y; Kawara K; Sasaki Y
    J Natl Cancer Inst; 2008 Feb; 100(3):224-5; author reply 225. PubMed ID: 18230796
    [No Abstract]   [Full Text] [Related]  

  • 12. [Relationship between UGT1A and irinotecan-related toxicity].
    Xu JM
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):241-3. PubMed ID: 23985249
    [No Abstract]   [Full Text] [Related]  

  • 13. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
    Rhodes KE; Zhang W; Yang D; Press OA; Gordon M; Vallböhmer D; Schultheis AM; Lurje G; Ladner RD; Fazzone W; Iqbal S; Lenz HJ
    Drug Metab Lett; 2007 Jan; 1(1):23-30. PubMed ID: 19356014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of irinotecan disposition and toxicity: a review.
    Fujita K; Sparreboom A
    Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Importance and practice of UGT1A1 polymorphisms].
    Hazama S; Oka M
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():351-4. PubMed ID: 22213983
    [No Abstract]   [Full Text] [Related]  

  • 16. Moving beyond fluorouracil for colorectal cancer.
    Mayer RJ
    N Engl J Med; 2000 Sep; 343(13):963-4. PubMed ID: 11006373
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Kim HT; Lee JS
    Lung Cancer; 2008 Jan; 59(1):69-75. PubMed ID: 17766002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment with CPT-11 based on the UGT1A1 genetic polymorphism].
    Nishi T; Komaki T; Hamamoto Y
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():545-9. PubMed ID: 22214020
    [No Abstract]   [Full Text] [Related]  

  • 19. [CPT-11: new drug for metastatic colorectal cancer].
    Barone C; Pozzo C; Cassano A
    Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
    [No Abstract]   [Full Text] [Related]  

  • 20. Searching for the Holy Grail of oncology.
    Higa GM
    Am J Health Syst Pharm; 2006 Nov; 63(22):2260-2. PubMed ID: 17090748
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.